Psoriasis and palmoplantar pustulosis associated with tumor necrosis factor-α inhibitors: The mayo clinic experience, 1998 to 2010

Journal of the American Academy of Dermatology

Volumn 67, Issue 5, 2012, Pages e179-e185

  Shmidt, Eugenia ^a   Wetter, David A ^b   Ferguson, Sara B ^c   Pittelkow, Mark R ^b  

^a MAYO CLINIC COLLEGE OF MEDICINE   (United States)

^b MAYO CLINIC   (United States)

^c Centre Medical and Surgical Associates   (United States)

Author keywords

Adalimumab; Etanercept; Infliximab; Palmoplantar pustulosis; Plaque psoriasis; Psoriasis; Tumor necrosis factor inhibitor

Indexed keywords

ADALIMUMAB; IMMUNOGLOBULIN G; INFLIXIMAB; MONOCLONAL ANTIBODY; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; CHEMICALLY INDUCED DISORDER; CROHN DISEASE; DISEASE COURSE; DRUG ANTAGONISM; FEMALE; HUMAN; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; PSORIASIS; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ARTHRITIS, RHEUMATOID; CROHN DISEASE; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; RETROSPECTIVE STUDIES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84872675083     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2011.05.038     Document Type: Article

References (23)

1. Schottelius AJ, Moldawer LL, Dinarello CA, Asadullah K, Sterry W, Edwards CK III. Biology of tumor necrosis factor-a: implications for psoriasis. Exp Dermatol 2004;13:193-222
2. Furst DE, Keystone EC, Breedveld FC, Kalden JR, Smolen JS, Antoni CE, et al. Updated consensus statement on tumour necrosis factor blocking agents for the treatment of rheumatoid arthritis and other rheumatic diseases (April 2001). Ann Rheum Dis 2001;60(Suppl):III2-5
3. Sobell JM. Overview of biologic agents in medicine and dermatology. Semin Cutan Med Surg 2005;24:2-9
4. Mease P. TNFa therapy in psoriatic arthritis and psoriasis. Ann Rheum Dis 2004;63:755-8
5. Zaba LC, Suarez-Farinas M, Fuentes-Duculan J, Nograles KE, Guttman-Yassky E, Cardinale I, et al. Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genes. J Allergy Clin Immunol 2009;124: 1022-10.e1-395
6. Zakharova M, Ziegler HK. Paradoxical anti-inflammatory actions of TNF-α: inhibition of IL-12 and IL-23 via TNF receptor 1 in macrophages and dendritic cells. J Immunol 2005;175: 5024-33
7. Tobin AM, Kirby B. TNFa inhibitors in the treatment of psoriasis and psoriatic arthritis. BioDrugs 2005;19:47-57
8. Wollina U, Hansel G, Koch A, Schonlebe J, Kostler E, Haroske G. Tumor necrosis factor-a inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients [Erratum in Am J Clin Dermatol 2008;9:347]. Am J Clin Dermatol 2008;9:1-14
9. Ko JM, Gottlieb AB, Kerbleski JF. Induction and exacerbation of psoriasis with TNF-blockade therapy: A review and analysis of 127 cases. J Dermatolog Treat 2009;20:100-8
10. Collamer AN, Battafarano DF. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: Clinical features and possible immunopathogenesis. Semin Arthritis Rheum 2010; 40:233-40
11. de Gannes GC, Ghoreishi M, Pope J, Russell A, Bell D, Adams S, et al. Psoriasis and pustular dermatitis triggered by TNF- [alpha] inhibitors in patients with rheumatologic conditions. Arch Dermatol 2007;143:223-31
12. Sfikakis PP, Kollias G. Tumor necrosis factor biology in experimental and clinical arthritis. Curr Opin Rheumatol 2003;15:380-6
13. Berg EL, Yoshino T, Rott LS, Robinson MK, Warnock RA, Kishimoto TK, et al. The cutaneous lymphocyte antigen is a skin lymphocyte homing receptor for the vascular lectin endothelial cell-leukocyte adhesion molecule 1. J Exp Med 1991;174:1461-6
14. Flier J, Boorsma DM, van Beek PJ, Nieboer C, Stoof TJ, Willemze R, et al. Differential expression of CXCR3 targeting chemokines CXCL10, CXCL9, and CXCL11 in different types of skin inflammation. J Pathol 2001;194:398-405
15. Carter JD, Gerard HC, Hudson AP. Psoriasiform lesions induced by tumor necrosis factor antagonists: A skin-deep medical conundrum. Ann Rheum Dis 2008;67:1181-3
16. Blumberg H, Dinh H, Dean C Jr, Trueblood ES, Bailey K, Shows D, et al. IL-1RL2 and its ligands contribute to the cytokine network in psoriasis. J Immunol 2010;185:4354-62
17. Guilloteau K, Paris I, Pedretti N, Boniface K, Juchaux F, Huguier V, et al. Skin inflammation induced by the synergistic action of IL-17A, IL-22, oncostatin M, IL-1a, and TNF-α recapitulates some features of psoriasis. J Immunol doi: 10.4049/jimmunol. 0902464. Published online March 24, 2010
18. Viguier M, Guigue P, Pages C, Smahi A, Bachelez H. Successful treatment of generalized pustular psoriasis with the interleukin- 1-receptor antagonist Anakinra: Lack of correlation with IL1RN mutations. Ann Intern Med 2010;153:66-7
19. Mizutani H, Ohmoto Y, Kupper TS, Shimizu M. Endogenous neutralizing anti-IL-1 alpha autoantibodies in inflammatory skin diseases: Possible natural inhibitor for over expressed epidermal IL-1. J Dermatol Sci 1998;20:63-71
20. Aksentijevich I, Masters SL, Ferguson PJ, Dancey P, Frenkel J, van Royen-Kerkhoff A, et al. An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. N Engl J Med 2009;360:2426-37
21. Weaver AL. Differentiating the new rheumatoid arthritis biologic therapies. J Clin Rheumatol 2003;9:99-114
22. Enbrel (etanercept) [package insert]. Seattle, WA: Immunex Corp; 2002
23. Tsankov N, Kazandjieva J, Drenovska K. Drugs in exacerbation and provocation of psoriasis. Clin Dermatol 1998;16:333-51.